The Experts below are selected from a list of 2466 Experts worldwide ranked by ideXlab platform
Leo W Buss - One of the best experts on this subject based on the ideXlab platform.
-
the selective myosin ii inhiBitor BleBBistatin reversiBly eliminates gastrovascular flow and stolon tip pulsations in the colonial hydroid podocoryna carnea
PLOS ONE, 2015Co-Authors: Noah Connally, Christopher P Anderson, Jules E Bolton, Edward W Bolton, Leo W BussAbstract:BleBBistatin reversiBly disrupted Both stolon tip pulsations and gastrovascular flow in the colonial hydroid Podocoryna carnea. Epithelial longitudinal muscles of polyps were unaffected By BleBBistatin, as polyps contracted when challenged with a pulse of KCl. <B>LatrunculinB> B, which sequesters G actin preventing F actin assemBly, caused stolons to retract, exposing focal adhesions where the tip epithelial cells adhere to the suBstratum. These results are consistent with earlier suggestions that non-muscle myosin II provides the motive force for stolon tip pulsations and further suggest that tip oscillations are functionally coupled to hydrorhizal axial muscle contraction.
Richard Treisman - One of the best experts on this subject based on the ideXlab platform.
-
rpel family rhogaps link rac cdc42 gtp loading to g actin availaBility
Nature Cell Biology, 2019Co-Authors: Jessica Diring, Stephane Mouilleron, Neil Q. Mcdonald, Richard TreismanAbstract:RPEL proteins, which contain the G-actin-Binding RPEL motif, coordinate cytoskeletal processes with actin dynamics. We show that the ArhGAP12- and ArhGAP32-family GTPase-activating proteins (GAPs) are RPEL proteins. We determine the structure of the ArhGAP12/G-actin complex, and show that G-actin contacts the RPEL motif and GAP domain sequences. G-actin inhiBits ArhGAP12 GAP activity, and this requires the G-actin contacts identified in the structure. In B16 melanoma cells, ArhGAP12 suppresses Basal Rac and Cdc42 activity, F-actin assemBly, invadopodia formation and experimental metastasis. In this setting, ArhGAP12 mutants defective for G-actin Binding exhiBit more effective downregulation of Rac GTP loading following HGF stimulation and enhanced inhiBition of Rac-dependent processes, including invadopodia formation. Potentiation or disruption of the G-actin/ArhGAP12 interaction, By treatment with the actin-Binding drugs <B>LatrunculinB> B or cytochalasin D, has corresponding effects on Rac GTP loading. The interaction of G-actin with RPEL-family rhoGAPs thus provides a negative feedBack loop that couples Rac activity to actin dynamics.
Neil Q. Mcdonald - One of the best experts on this subject based on the ideXlab platform.
-
rpel family rhogaps link rac cdc42 gtp loading to g actin availaBility
Nature Cell Biology, 2019Co-Authors: Jessica Diring, Stephane Mouilleron, Neil Q. Mcdonald, Richard TreismanAbstract:RPEL proteins, which contain the G-actin-Binding RPEL motif, coordinate cytoskeletal processes with actin dynamics. We show that the ArhGAP12- and ArhGAP32-family GTPase-activating proteins (GAPs) are RPEL proteins. We determine the structure of the ArhGAP12/G-actin complex, and show that G-actin contacts the RPEL motif and GAP domain sequences. G-actin inhiBits ArhGAP12 GAP activity, and this requires the G-actin contacts identified in the structure. In B16 melanoma cells, ArhGAP12 suppresses Basal Rac and Cdc42 activity, F-actin assemBly, invadopodia formation and experimental metastasis. In this setting, ArhGAP12 mutants defective for G-actin Binding exhiBit more effective downregulation of Rac GTP loading following HGF stimulation and enhanced inhiBition of Rac-dependent processes, including invadopodia formation. Potentiation or disruption of the G-actin/ArhGAP12 interaction, By treatment with the actin-Binding drugs <B>LatrunculinB> B or cytochalasin D, has corresponding effects on Rac GTP loading. The interaction of G-actin with RPEL-family rhoGAPs thus provides a negative feedBack loop that couples Rac activity to actin dynamics.
Paul L Kaufman - One of the best experts on this subject based on the ideXlab platform.
-
EFFECTS OF <B>LatrunculinB> B ON OUTFLOW FACILITY, INTRAOCULAR PRESSURE, CORNEAL THICKNESS, AND MIOTIC AND ACCOMMODATIVE RESPONSES TO PILOCARPINE IN MONKEYS
2015Co-Authors: Baohe Tian, Paul L KaufmanAbstract:Purpose: To determine if low doses of topical <B>LatrunculinB> B (LAT-B) will increase outflow facility and decrease intraoc-ular pressure (IOP) without adversely affecting the cornea, and inhiBit miotic and accommodative responses to pilo-carpine, in ocular normotensive monkeys. Methods: Intraocular pressure was measured By Goldmann tonometry Before and after one and nine dose(s) of 0.005% and 0.01 % topical LAT-B/vehicle given twice daily on successive weeks. Outflow facility was then measured By perfusion following 15 doses. Central corneal thickness was measured By ultrasonic pachymetry Before and after one and nine dose(s) of 0.01 % LAT-B/vehicle. Pupillary diameter (calipers) and accommodation (refractometry) Before and after one dose of 0.005 % and 0.02 % LAT-B were determined. Results: LAT-B dose-dependently decreased IOP, multiple doses more than a single dose. Maximal hypotension after on
-
cytoskeletal drugs prevent posterior capsular opacification in human lens capsule in vitro
Graefes Archive for Clinical and Experimental Ophthalmology, 2012Co-Authors: Jeyalakshmi Sureshkumar, Aravind Haripriya, Veerappan Muthukkaruppan, Paul L Kaufman, Baohe TianAbstract:Background To determine whether the cytoskeletal drugs H-7 and <B>LatrunculinB> B (LAT-B) inhiBit posterior capsular opacification (PCO) in the cultured human lens capsular Bag.
-
effect of low dose <B>LatrunculinB> B on anterior segment physiologic features in the monkey eye
Archives of Ophthalmology, 2004Co-Authors: Mehmet Okka, Baohe Tian, Paul L KaufmanAbstract:OBJECTIVES To determine if low doses of topical <B>LatrunculinB> B (LAT-B) will increase outflow facility and decrease intraocular pressure without damaging the cornea and if they will inhiBit miotic and accommodative responses to pilocarpine in monkeys. METHODS We measured intraocular pressure (Goldmann tonometry) Before and after 1 and 9 doses of 0.005% and 0.01% topical LAT-B and vehicle given twice daily on successive weeks; outflow facility (perfusion) following 15 doses; central corneal thickness (ultrasonic pachymetry) Before and after 1 and 9 doses of 0.01% LAT-B and vehicle; pupillary diameter (calipers); and accommodation (refractometry) Before and after 1 dose of 0.005% and 0.02% LAT-B. RESULTS <B>LatrunculinB>-B dose-dependently decreased intraocular pressure, multiple doses more than a single dose. Maximal mean +/- SEM hypotension after 1 dose was 2.5 +/- 0.3 mm Hg (0.005% LAT-B; n = 8; P<.001) or 2.7 +/- 0.6 mm Hg (0.01% LAT-B; n = 8; P<.005); maximal mean +/- SEM hypotension after 9 doses was 3.2 +/- 0.5 mm Hg (0.005% LAT-B; n = 8; P<.001) or 4.4 +/- 0.6 mm Hg (0.01% LAT-B; n = 8; P<.001). Outflow facility was increased By mean +/- SEM 75% +/- 13% (n = 7; P<.005). Central corneal thickness was not changed after 1 or 9 doses of 0.01% LAT-B. Miotic and accommodative responses to intramuscular pilocarpine were dose-dependently inhiBited. With 0.02% LAT-B, inhiBition of miosis was suBstantial, whereas the inhiBition of accommodation was only aBout 25%. With 0.005% LAT-B, the effects were trivial. CONCLUSIONS In ocular normotensive monkeys, 0.005% and 0.01% LAT-B administered topically increases outflow facility and/or decreases intraocular pressure without corneal effects. Multiple doses reduce intraocular pressure more than a single dose. <B>LatrunculinB>-B dose-dependently relaxes the iris sphincter and ciliary muscle, with some separation of miotic and accommodative effects. Clinical Relevance Multiple treatments with low topical doses of LAT-B may suBstantially reduce outflow resistance in eyes with glaucoma without adversely affecting the cornea.
-
effects of <B>LatrunculinB> B on outflow facility intraocular pressure corneal thickness and miotic and accommodative responses to pilocarpine in monkeys
Transactions of the American Ophthalmological Society, 2004Co-Authors: Mehmet Okka, Baohe Tian, Paul L KaufmanAbstract:Purpose: To determine if low doses of topical <B>LatrunculinB> B (LAT-B) will increase outflow facility and decrease intraocular pressure (IOP) without adversely affecting the cornea, and inhiBit miotic and accommodative responses to pilocarpine, in ocular normotensive monkeys. Methods: Intraocular pressure was measured By Goldmann tonometry Before and after one and nine dose(s) of 0.005% and 0.01% topical LAT-B/vehicle given twice daily on successive weeks. Outflow facility was then measured By perfusion following 15 doses. Central corneal thickness was measured By ultrasonic pachymetry Before and after one and nine dose(s) of 0.01% LAT-B/vehicle. Pupillary diameter (calipers) and accommodation (refractometry) Before and after one dose of 0.005% and 0.02% LAT-B were determined. Results: LAT-B dose-dependently decreased IOP, multiple doses more than a single dose. Maximal hypotension after one dose was 2.5 ± 0.3 mm Hg (0.005% LAT-B; n = 8; P < .001) or 2.7 ± 0.6 mm Hg (0.01% LAT-B; n = 8; P < .005); maximal hypotension after nine doses was 3.2 ± 0.5 mm Hg (0.005% LAT-B; n = 8; P < .001) or 4.4 ± 0.6 mm Hg (0.01% LAT-B; n = 8; P < .001). Outflow facility was increased By 75 ± 13% (n = 7; P < .005). Central corneal thickness was not changed after one or nine dose(s) of 0.01% LAT-B. The miotic and accommodative responses to intramuscular pilocarpine were dose-dependently inhiBited. At 0.02% LAT-B, the inhiBition of miosis was essentially complete when compared with the pre-LAT-B value, whereas the inhiBition of accommodation was only aBout 25%. At 0.005% LAT-B, the effects were trivial. Conclusions: In ocular normotensive monkeys, 0.005/0.01% LAT-B administered topically increases outflow facility and/or decreases IOP, But does not affect the cornea. Multiple doses reduce IOP more than a single dose. LAT-B dosedependently relaxes the iris sphincter and ciliary muscle, with some separation of the miotic and accommodative effects.
Jessica Diring - One of the best experts on this subject based on the ideXlab platform.
-
rpel family rhogaps link rac cdc42 gtp loading to g actin availaBility
Nature Cell Biology, 2019Co-Authors: Jessica Diring, Stephane Mouilleron, Neil Q. Mcdonald, Richard TreismanAbstract:RPEL proteins, which contain the G-actin-Binding RPEL motif, coordinate cytoskeletal processes with actin dynamics. We show that the ArhGAP12- and ArhGAP32-family GTPase-activating proteins (GAPs) are RPEL proteins. We determine the structure of the ArhGAP12/G-actin complex, and show that G-actin contacts the RPEL motif and GAP domain sequences. G-actin inhiBits ArhGAP12 GAP activity, and this requires the G-actin contacts identified in the structure. In B16 melanoma cells, ArhGAP12 suppresses Basal Rac and Cdc42 activity, F-actin assemBly, invadopodia formation and experimental metastasis. In this setting, ArhGAP12 mutants defective for G-actin Binding exhiBit more effective downregulation of Rac GTP loading following HGF stimulation and enhanced inhiBition of Rac-dependent processes, including invadopodia formation. Potentiation or disruption of the G-actin/ArhGAP12 interaction, By treatment with the actin-Binding drugs <B>LatrunculinB> B or cytochalasin D, has corresponding effects on Rac GTP loading. The interaction of G-actin with RPEL-family rhoGAPs thus provides a negative feedBack loop that couples Rac activity to actin dynamics.